HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019
(WorldNews Health)

November 11, 2019 HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019 Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka, Ph.D.) today announced that Phase 3 results of Vadadustat (MT-6548) in Japan have been presented at American Society of Nephrology (ASN) Kidney Week 2019 from November 5 to November 10, 2019 in Washington DC. MTPC has submitted to the Ministry of Health, Labour and Welfare in Japan an application for the manufacturing and marketing approval of Vadadustat (MT-6548) on July 2019.